ARTICLE | Company News
China Biopharma infectious news
December 3, 2007 8:00 AM UTC
CBPC will refocus on higher-margin vaccines and specialty drugs and will "move away from" developing and marketing lower-margin vaccines, such at its marketed Yuganning influenza vaccine. The company began distributing specialty pharmaceuticals under a March deal with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), including Takeda's Dasen serrapeptase tablets to treat inflammation. ...